Year: 2021

Data Presented in Poster Presentation at American Society of Hematology Annual Meeting BURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease (aGVHD) in patients receiving allogeneic hematopoietic cell transplantation (bone marrow transplantation). The data will be presented today in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Bone marrow transplantation is a potentially curative therapy for patients with a variety of blood disorders, including blood cancers, certain solid cancers, hemoglobinopathies such as sickle cell disease,...

BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced safety and dose-response data from its Phase 1 clinical trial of ANX009, the company’s subcutaneously administered product candidate that is designed to block the activity of C1q and the entire classical complement pathway. In addition, Annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA). The data were presented during two poster sessions at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. “We are pleased to present these data at ASH, which further...

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic...

SANTA CLARA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) —  AMD (NASDAQ: AMD) today announced that AMD President and CEO Dr. Lisa Su will host its 2022 Product Premiere on January 4, 2022. Dr. Su will highlight innovations and solutions featuring upcoming AMD Ryzen™ processors and AMD Radeon™ graphics. The AMD Product Premiere livestream will be accessible to the public beginning at 10 a.m. EST on Tuesday, January 4 at AMD.com; replays will be available after the conclusion of the livestream event. Supporting Resources:Visit the AMD 2022 Product Premiere landing page Follow AMD on Twitter and LinkedIn Become a fan of AMD on FacebookAbout AMDFor 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies ― the building blocks for gaming, immersive platforms and the datacenter. Hundreds...

Telehealth Innovator Launches into Public Markets VANCOUVER, British Columbia, Dec. 13, 2021 (GLOBE NEWSWIRE) — UniDoc Health Corp. (CSE: UDOC) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to announce its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on December 13, 2021, under the ticker symbol “UDOC.” Additional information is now available on the Company website at www.unidoctor.com. UniDoc is a virtual health/telehealth solutions company. The Company’s primary offering will be the Virtual Care Solutions Model, a proprietary, customizable, and comprehensive telehealth solution that integrates a range of physical products, web-based services, and analytical tools, along with access to the Company’s developing network of healthcare...

GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers   Study results provide proof of concept to support the continued development of GBT601 GBT to host investor conference call and webcast today at 12:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor, that demonstrated average hemoglobin (Hb) occupancy greater than 30% and improvements in hematologic parameters in a cohort of six patients with sickle cell disease...

Next-Generation SOLO EV to be Assembled in the U.S.; Currently in Validation Testing at Dedicated Joint Testing Facility with Partner GLV Automotive VANCOUVER, British Columbia, Dec. 13, 2021 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, today announced that the 2023 SOLO EV – to be assembled at the Company’s Mesa Manufacturing Facility in Arizona for delivery to the public in late 2022 – is now undergoing validation testing at a dedicated temporary testing facility. The validation testing is intended to ensure the new 2023 SOLO EV – which implements a suite of upgrades based on customer feedback – meets all desired specifications. The validation testing is taking...

WOODSIDE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth”), an externally managed business development company, today announced that it has agreed to issue $70 million in aggregate principal amount of 4.25% Series 2021A Senior Notes due 2026 (the “ 2026 Senior Notes”). The Notes will be issued in two closings. The initial issuance of $20 million 2026 Senior Notes closed today, December 10, 2021. The issuance of the remaining $50 million of 2026 Senior Notes is expected to occur on or about February 10, 2022. Each closing is subject to customary closing conditions. The 2026 Senior Notes have been offered only to institutional accredited investors (as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)) in reliance on Section 4(a)(2) of the...

Unrivaled Retains Ownership of the Dispensary License SANTA ANA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX: UNRV) (“Unrivaled” or the “Company”) announced today the execution of an agreement to sell the Company’s real property and building located on Dyer Road in Santa Ana, CA (the “Dyer Property”) for $13.4 million. The sale is expected to close in January 2022, and the Company will retire $9.0 million of outstanding debt on the property. Notwithstanding the sale of the real estate at Dyer, the Company retains, through a wholly owned subsidiary that is not party to the sale, local approval to seek a license to open a cannabis dispensary at the Dyer building location. However, following the Company’s acquisition of the highly successful People’s dispensary, the Company is evaluating...